XML 42 R35.htm IDEA: XBRL DOCUMENT v3.25.2

Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment information for the three and six months ended June 30, 2025 and 2024 is as follows (in thousands):

		Three Months Ended June 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	26,771			$	—			$	—			$	26,771
Cost of revenues			1,151				—				—				1,151
Gross profit			25,620				—				—				25,620
Operating expenses excluding cost of revenues:
Selling and marketing			15,194				—				—				15,194
Research and development			3,337				88				—				3,425
General and administrative			2,857				1,970				2				4,829
Loss on disposal of assets, net			1				—				—				1
Total operating expenses excluding cost of revenues			21,389				2,058				2				23,449
Income (loss) from operations			4,231				(2,058	)			(2	)			2,171
Other (expense) income, net			(237	)			92				—				(145	)
Change in fair value of warrant liability			—				212				—				212
Income tax expense			(662	)			—				—				(662	)
Net income (loss)		$	3,332			$	(1,754	)		$	(2	)		$	1,576
Supplemental disclosure of stock-based compensation expense:
Cost of revenue		$	47			$	—			$	—			$	47
Selling and marketing			29				—				—				29
General and administrative			273				557				—				830
Stock-based compensation total		$	349			$	557			$	—			$	906

		Six Months Ended June 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	48,829			$	—			$	—			$	48,829
Cost of revenues			2,045				—				—				2,045
Gross profit			46,784				—				—				46,784
Operating expenses excluding cost of revenues:
Selling and marketing			26,035				—				—				26,035
Research and development			6,366				154				—				6,520
General and administrative			6,413				3,366				5				9,784
Loss on disposal of assets, net			1				—				—				1
Total operating expenses excluding cost of revenues			38,815				3,520				5				42,340
Income (loss) from operations			7,969				(3,520	)			(5	)			4,444
Other (expense) income, net			(175	)			137				—				(38	)
Change in fair value of warrant liability			—				2,467				—				2,467
Income tax expense			(1,563	)			—				—				(1,563	)
Net income (loss)		$	6,231			$	(916	)		$	(5	)		$	5,310
Supplemental disclosure of stock-based compensation expense:
Cost of revenue		$	47			$	—			$	—			$	47
Selling and marketing			29				—				—				29
General and administrative			351				986				—				1,337
Stock-based compensation total		$	427			$	986			$	—			$	1,413

		Three Months Ended June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	25,225			$	—			$	—			$	25,225
Cost of revenues			770				—				—				770
Gross profit			24,455				—				—				24,455
Operating expenses excluding cost of revenues:
Selling and marketing			14,414				—				—				14,414
Research and development			3,077				278				—				3,355
General and administrative			2,549				874				1				3,424
Loss on disposal of assets, net			68				—				—				68
Total operating expenses excluding cost of revenues			20,108				1,152				1				21,261
Income (loss) from operations			4,347				(1,152	)			(1	)			3,194
Change in fair value of warrant liability			—				2,913				—				2,913
Other income (expense), net			53				(125	)			—				(72	)
Income tax expense			(1,497	)			—				—				(1,497	)
Net income		$	2,903			$	1,636			$	(1	)		$	4,538
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	16			$	—			$	16
Stock-based compensation total		$	—			$	16			$	—			$	16

		Six Months Ended June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	52,397			$	—			$	—			$	52,397
Cost of revenues			1,749				—				—				1,749
Gross profit			50,648				—				—				50,648
Operating expenses excluding cost of revenues:
Selling and marketing			26,956				—				—				26,956
Research and development			5,086				451				—				5,537
General and administrative			4,806				2,015				1				6,822
Loss on disposal of assets, net			68				—				—				68
Total operating expenses excluding cost of revenues			36,916				2,466				1				39,383
Income (loss) from operations			13,732				(2,466	)			(1	)			11,265
Change in fair value of warrant liability			—				7,201				—				7,201
Other income (expense), net			115				(65	)			—				50
Income tax expense			(4,043	)			—				—				(4,043	)
Net income		$	9,804			$	4,670			$	(1	)		$	14,473
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	27			$	—			$	27
Stock-based compensation total		$	—			$	27			$	—			$	27

The table below presents total assets as of June 30, 2025 and December 31, 2024.

		June 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	121,142			$	31,139			$	365			$	152,646

		December 31, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	114,248			$	10,790			$	368			$	125,406

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

		Six Months Ended June 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	378			$	—			$	—			$	378

		Six Months Ended June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	1,673			$	14			$	—			$	1,687

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration